Introduction {#S1}
============

Newborn bloodspot screening (NBS) is the longest running and most successful population screening program worldwide ([@B1]). NBS tests newborns within the first days of life for multiple serious conditions ([@B2]). The traditional aim of NBS is to prevent serious consequences for the newborn by enabling timely diagnoses and treatment for early onset childhood conditions ([@B3]). In recent years, technological developments, changes in understanding of conditions, and new treatments, have fueled the expansion of NBS ([@B4], [@B5]). The aim of this study is to explore issues influencing each phase of the policy cycle. In doing so, this study provides policy makers insight in the pressures facing NBS to inform them on approaches to successfully guide programs into the future.

An archetypal example of the policy pressures facing NBS was the advent of tandem mass spectrometry (MS/MS), and the resultant impact it had upon programs worldwide. This technology emerged in the 1990s and made it possible to test for several conditions at once in a cost-effective manner ([@B4], [@B5]). Correspondingly, several programs adopted the technology and significantly increased the number of conditions screened. Programs using these technologies regularly screen from 9 to over 50 conditions ([@B1], [@B6]--[@B9]). Even more than MS/MS, genetic technologies may enable screening for a larger number of conditions ([@B3], [@B10], [@B11]). Debate abounds in the academic literature on the appropriateness of expanding NBS ([@B4], [@B10], [@B12]): some authors advocate for targeted approaches ([@B13], [@B14]); while elsewhere next generation sequencing is being applied in the research setting to study it's potential for NBS ([@B15], [@B16]).

Previous expansions and the divergent programs that have evolved, suggest that the emergence of genetic technologies is likely to be a significant turning point for NBS. Given the reach of NBS, that NBS tests our most vulnerable population, and the potential to increasingly expand programs, it is essential that decisions on what to screen are carefully considered. Thus policy approaches are needed which can successfully navigate in the changing environment ([@B14]). It can be expected that an expansion occurring in some countries will become an example of what is possible for other countries ([@B17]). At a minimum, further debate will emerge on the pros and cons of expanded screening, and experts, consumers, and advocacy groups are likely to increase calls for screening for specific conditions ([@B17]). The emergence of debates on further expanding NBS presents decision makers worldwide with the challenge of weighing the benefits and harms of screening in the changing landscape of NBS. Policy frameworks, which are developed in light of the range of policy issues, will be essential for policy makers to ensure their programs can effectively respond to the pressures facing the program, now and in the future.

Given the pressures for NBS, the current study aims to identify what the scientific literature outlines are the key policy considerations currently facing NBS. This is achieved by exploring issues pertinent to NBS policy making, through the lens of the policy cycle ([@B10]): (a) agenda setting, (b) policy advice, (c) policy decision, (d) implementation, and (e) evaluation. Without detailing current developments in genomic technologies, we aim to explore issues influencing each phase of the policy cycle. In doing so, this study will enable policy makers responsible for existing or emerging NBS programs to consider the best policy structure to respond to the changing environment in which NBS operates.

Methods {#S2}
=======

We explored academic literature to summarize relevant factors pertinent to policy making for NBS. International policy making processes have been recently reviewed elsewhere ([@B1], [@B12]). The current study builds upon what is known about the tangible policy making process, by highlighting issues facing NBS identified in academic literature. This then provides policy makers an outline of the issues that should be considered in the development of policies. To be included in the review an article needed to discuss one or more of the following topics: nomination of a condition (agenda setting); consideration of a condition (policy advice); deciding on a condition (policy decision); addition of a condition (implementation); or quality assurance and improvement (evaluation). Articles were also included if they discussed all elements of the policy cycle, such as mention of a comprehensive policy framework for NBS policy making.

We searched PubMed for articles regarding *newborn screening* and *policy*. We combined the two key search terms with the following search terms: 1. *program development*, 2. *decision-making*, 3. *governance*, 4. *management*, 5. *perspective*, 6. *future*, and 7. *disease* or *condition*. Only English publications on dried bloodspot screening were included. Articles concerning other types of newborn screening (e.g., hearing, hip dysplasia) were excluded, because we wanted to focus on the complex policy making specific to bloodspot screening.

Results {#S3}
=======

The initial literature search identified 59 articles. Twenty-seven articles discussed one or more of the elements of the policy cycle (Table [S1](#SM2){ref-type="supplementary-material"} in Supplementary Material). Most literature originated from western societies, predominantly the USA (13 of 27 articles, Table [S1](#SM2){ref-type="supplementary-material"} in Supplementary Material) and was initiated from a clinical background rather than a public health background (Figure [S1](#SM1){ref-type="supplementary-material"} in Supplementary Material). The main technology discussed in the articles shows a shift through time from MS/MS toward discussing genetic technologies as the challenge for NBS: 3 of 13 articles until 2008 discuss mainly genetic technologies and 6 of 14 published since 2009 (Table [S1](#SM2){ref-type="supplementary-material"} in Supplementary Material). Recent articles discussing MS/MS report on results from current screening programs or previous decision-making processes ([@B18]). The following outlines the results, stepping through the policy cycle.

Agenda Setting: Nominating a Condition {#S3-1}
--------------------------------------

The review highlighted two approaches to nominating a condition. The first is a structured approach focused on horizon scanning; the second approach is much more *ad hoc* and influenced by external drivers, such as advocacy ([@B18]--[@B20]).

The structured, horizon scanning approach generally includes an independent body that undertakes horizon scanning to identify a range of relevant conditions to evaluate for NBS and support expansion through an evidence-based process ([@B10], [@B21], [@B22]). Such an approach has been successfully used by several countries in agenda setting based on an objective threshold of criteria ([@B18], [@B22]). In horizon scanning, potential conditions are identified and recommended for further in-depth review, through initial assessment of criteria. Contrary to the organized horizon scanning approach, the majority of the literature focused on an *ad hoc* approach. In this approach, conditions became the focus of an assessment for NBS in response to new technologies, broader disease definition, insight into pathophysiology, and advocacy ([@B5], [@B23]--[@B26]). In the past, NBS policy direction and program expansion have been strongly influenced by technological drivers, often evaluated *ad hoc* ([@B18]--[@B20]).

Advocacy is a key driver for change within NBS. Pressure by consumers, clinicians, and scientists to screen for a condition dates back to the very first condition screened in NBS, phenylketonuria (PKU). NBS for PKU was advocated by Dr Guthrie, whose son was born mentally handicapped and whose niece experienced intellectual disability due to undiagnosed and unmanaged PKU ([@B5]). Dr Guthrie developed a test to identify the condition and advocated for mass screening of PKU through community support groups ([@B5]). Recent examples of advocate pressure leading to the introduction of a condition include in the instance of X-linked adrenoleukodystrophy and Krabbe disease in the USA ([@B5], [@B10], [@B27]). However, the benefits of screening, for Krabbe are disputed in literature and referred to as "dangerous and expensive" ([@B27]).

Policy Advice: Assessment of a Condition {#S3-2}
----------------------------------------

Within the literature reviewed, there was unanimous support for a robust assessment process based on criteria. However, a key issue relating to the assessment of nominated conditions centered on the appropriateness of using criteria originating from the Wilson and Jungner principles ([@B10], [@B28], [@B29]). Criticisms are voiced that the Wilson and Jungner principles are developed to evaluate individual conditions, while modern day technology pushes toward the possibility and sometimes the need to evaluate groups of conditions at once ([@B30], [@B31]). Furthermore, there is no objective tool developed from the Wilson and Jungner principles, which leaves them open to interpretation into different criteria between programs ([@B31]).

While the need to assess harms and benefits was a repeated theme in the articles, there is no agreed-upon threshold for benefit ([@B10], [@B22], [@B29]). This is essential to effectively explore the benefits and harms of screening, to ensure that the former outweighs the latter. The benefit of screening is intrinsically related to the primary aim of screening, which is predominantly to avoid preventable harm in newborns. The aim and beneficiary screening should both be specified in policies, as they are open to interpretation ([@B9], [@B32], [@B33]). That is, to support assessing the appropriateness of a condition, there needs to a clear understanding of who will benefit from screening, what is the perceived benefit, and how should it be weighed in decisions ([@B10], [@B22]). In general, three groups were mentioned as potential beneficiaries of NBS: the child, the family, and/or society ([@B34]). In the recent report from the Health Council of the Netherlands, the beneficiary of screening was specifically defined as the child. Consequently, this lead to conditions without clear clinical benefits to the child to be assessed as inappropriate for inclusion within NBS ([@B12]).

Policy Decision: Deciding on a Condition {#S3-3}
----------------------------------------

The literature focused on two key areas when deciding whether to screen a condition. The first focused on who makes the decision, and the second focused on the evidence on which the decision is made. The literature was consistent in its recommendation for an overarching, independent, multidisciplinary group providing recommendations to government ([@B18], [@B24], [@B28]).

In terms of evidence, authors of the reviewed literature identified that decisions in NBS often need to be made based on incomplete information ([@B22]). A main concern identified in several articles, is the lack of data to support evidence-based decisions. There is the need for interoperable databases to collect sufficient data on the diseases considered and included in NBS ([@B10], [@B23], [@B35]). Alternatively, authors suggested that innovations in NBS should be implemented in a research paradigm, to facilitate data collection for policy decisions, and gain informed consent from parents participating with their child(ren) in the study ([@B22], [@B30], [@B33], [@B35]). Pilot studies are vital to the development of a strong evidence base to support decision-making regarding the addition of new conditions. As shown in Denmark, the Faroe Island, and Greenland, a pilot program of 7 years eventually provided information for evaluation and the subsequent decision to not include 11 conditions in the routine screening program in 2009 ([@B36]).

Implementation: Addition of a Condition {#S3-4}
---------------------------------------

Once a condition is approved for implementation in a NBS program, an implementation plan focusing on the different levels on which NBS operates and the information needed at each level should be developed ([@B21], [@B37], [@B38]). Issues across programs are similar when looking at implementation and relate to five fields: education, finances, logistics, politics, and culture ([@B5], [@B24]). These fields extend beyond "public health" to also include follow-up in the clinical setting. Key issues include the need for work flow across these fields to be coordinated, and ensuring professionals have the relevant skills and knowledge for the new condition(s) ([@B24], [@B39]). Issues to ensure skills and knowledge are particularly challenging where conditions are being identified in the pre-symptomatic phase, and there may be a lack of evidence or consensus in clinical guidelines. This will be further challenged if the preferred technology moves toward genome-based technologies, which can identify genetic variations that have implications for family members. These technologies will lead to issues relating to privacy and confidentiality, residual specimen storage and usage policies, and educational material to become even more pressing ([@B40]).

Evaluation: Quality Assurance and Improvement {#S3-5}
---------------------------------------------

Continuously monitoring, and improving a program is vital, particularly following the implementation of screening for a new condition ([@B30]). It is possible that a condition assessed as being appropriate to screen, will not meet the parameters upon which this decision was based. For example, the false positives or negatives recorded for a test within a trial period might not align with those that occur in the real world setting. Thus quality assurance (QA) is required to monitor the program's performance against defined targets to ensure it aligns with the anticipated outcomes ([@B22], [@B29], [@B34]).

QA provides essential ongoing assessment of feasibility, cost, and equitable delivery of testing ([@B10], [@B32], [@B37]). Some authors suggest principles for QA, such as clear guidelines on responsibilities throughout the chain of NBS; standards on aspects regarding confidentiality; and protocols for storage of blood spot specimens ([@B21]). Importantly, QA should be complemented by quality improvement (QI). QI builds upon QA, to drive improvements and achieve success. Issues for QI within NBS include managing the improvement process across the NBS system: from health-care professionals to laboratory experts. Ways to overcome fragmentation of providing information on the key indicators while gaining data on them from all parts of NBS can be providing training, develop written educational materials for parents and health-care professionals, and redesign laboratory slips for blood collection ([@B21]).

Policy Cycle in General {#S3-6}
-----------------------

Authors advocated a transparent, structured, and evidence-based process ([@B22], [@B25], [@B41]). Policy making for NBS can be governed both locally and nationally ([@B38], [@B42]). Governance is a process that focuses on balancing competing influences and demands ([@B43]). The need for harmonization of national policies is often referred to in literature: to ensure a national balance in competing interests and equity in access to early interventions ([@B29], [@B31]). A central body like a national or federal government should play a core role in overseeing NBS. In addition, consultation and engagement is a key theme, which some authors highlight should be managed through a multidisciplinary advisory committee providing advice through the policy cycle ([@B28]). An advisory committee could advise them on implementation, development, review, modification, and cessation of (parts of) NBS ([@B21], [@B29], [@B38]).

Discussion {#S4}
==========

Stepping through the policy cycle illustrated that NBS is on the precipice of great change. Programs are facing a wave of pressures, including in response to new treatments and new technologies. The history of NBS suggests the programs are flexible in responding to a continually changing environment. However, the historical *ad hoc* approach to adding conditions to NBS is recognized as potentially problematic in the light of future developments. Current NBS programs might contain conditions that have not been robustly evaluated through an agreed policy advice process. Future developments and challenges highlight that policy makers need to take stock of the issues facing the programs, and develop policies that will ensure safe and appropriate growth of programs ([@B22], [@B25], [@B41]).

The growing number of conditions that could be screened is a key issue for NBS programs, particularly in the face of pressures from next generation sequencing ([@B13], [@B44]). Moreover, the potentially growing number of conditions extends beyond what is technologically possible, to challenge the fundamental purpose of the programs. Internationally, there are increasing calls to move further beyond the traditional aim of NBS, and screen for "untreatable" conditions ([@B33], [@B34]). Untreatable conditions do not always have a certain treatment benefit or treatment is not urgently needed in the newborn period. For untreatable conditions to be implemented in NBS, some argue that the aim has to shift from clinical benefits solely for the child, to include family benefits ([@B24], [@B29]). Such a shift in the focus of beneficiary beyond the newborn, will lead to a vast increase in the number and type of conditions eligible for screening ([@B3], [@B22]): a great number of conditions may have family benefit through information on relevant reproductive options compared to a limited amount of conditions that have direct clinical benefit for the newborn ([@B34]).

The above issues overwhelmingly outline the need for robust and considered policy making for NBS. However, it is unclear whether such policy making can fully combat the pressures facing the program. Many nomination processes can still be considered passive where a nomination is awaited, instead of active horizon scanning for relevant conditions. Further, should there be a shift in focus or a push for more conditions to be screened, it is recommended that this be accompanied with consideration as to whether NBS is the right place to screen for such conditions. Specifically, in order to protect the programs and ensure they stay true to their aim, consideration should be given to preconception, prenatal, or screening during early childhood.

Our study has several limitations, data from the USA were overrepresented (13 of the 27 articles) and a sample of 27 articles might not be representative for international policy making in NBS. Further, the policy cycle is theoretical. As such, the recommendations from academic literature are prone to interpretational disparity between theory and practice. Nonetheless, this review shows relevant aspects in policy making and addresses gaps in the current processes. Our results suggests that there is the need for a structured and timely approach that responds to the changing environment.

Through a systematic, continuous policy process, NBS programs will be able to anticipate developments, as opposed to being reactive and heavily influenced by external drivers. A policy process that is developed in light of the issues raised here will help the programs to anticipate challenges and progress in a safe and effective way. A framework to facilitate this approach should be strived for. Only by making careful and considered decisions, can we ensure that NBS of the future is as successful as the existing programs we know today.
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